(MENAFN- Trend News Agency ) BAKU, Azerbaijan, Sept. 18
By Elnur Baghishov – Trend:
In general, 54 batches of 58.3 million doses of COVID-19 vaccine have been imported to Iran from February 3, 2021 to September 17, 2021, this was reflected in statistics of Islamic Republic of Iran Customs Administration (IRICA), Trend reports.
According to statistics, these vaccines were imported from China, Japan, Italy, Russia, South Korea and India.
Country
Types of vaccine
Batch
Doses
China
Sinopharm
31
48,726,396
Japan
AstraZeneca
3
2,911,810
Italy
COVAX
1
1,452,000
China
AstraZeneca
1
1,449,600
Russia
Sputnik V
12
1,345,000
Russia
AstraZeneca
2
963,000
South Korea
COVAX
1
700,800
Austria
AstraZeneca
2
650,000
India
Bharat Biotech
1
125,000
Total
54
58,323,606
Iran continues to monitor the coronavirus situation in the country. According to recent reports from Iranian officials, over 5.39 million people have been infected, and more than 116,000 people have already died.
Meanwhile, over 4.7 million people have reportedly recovered from the disease.
The country continues to apply strict measures to contain further spread. Reportedly, the disease was brought to Iran by a businessman from Iran's Qom city, who went on a business trip to China, despite official warnings. The man died later from the disease.
The Islamic Republic only announced its first infections and deaths from the coronavirus on Feb. 19.
The outbreak in the Chinese city of Wuhan - which is an international transport hub - began at a fish market in late December 2019.
The World Health Organization (WHO) on March 11 declared COVID-19 a pandemic. Some sources claim the coronavirus outbreak started as early as November 2019.
---
Follow the author on Twitter: @BaghishovElnur
MENAFN18092021000187011040ID1102818372
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.